GRAIL gets 7-2 FDA panel backing for Galleri cancer test

Mugglehead
By Theo MarchettiSep 23, 2026, 6:16 pm64 pts
The U.S. Food and Drug Administration's Molecular and Clinical Genetics Panel recommended on Sept. 23 that the benefits of the Galleri multi-cancer blood test outweigh its risks for the proposed screening population, STAT reported from the meeting. GRAIL, Inc. (NASDAQ: GRAL) received a 7-to-2 vote on that…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells 79

Harrelson and McConaughey Contemplate Whether They're Related in 'Brothers' 77

Oregon Officials Drop Plans to Increase Psilocybin Licensing Fees 75

Tennessee Appeals Court Upholds Reinstatement of Sheriff’s Deputy Fired After THC Test, Citing Legal CBD Use 74

Mainstream insurance companies push for cannabis industry access 74

GRAIL gets 7-2 FDA panel backing for Galleri cancer test 64

Ohio cannabis store reopens after brief health scare tied to vapes 62

Redman Debuts Muddy Waters Drinks at NECANN 2026 in Atlantic City 53

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.